Evidence map›Paper›PMID 36970615›Full record

ReviewFrontiers in bioengineering and biotechnology2023

2D-nanomaterials for AKI treatment.

Qiaohui Chen, Xiaoyuan Wang, Chao Yuan, Yayun Nan, Qiong Huang, Kelong Ai

Erratum issuedOpen access · goldFull text readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Qiaohui ChenDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xiaoyuan WangXiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China.
Chao YuanXiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China.
Yayun NanGeriatric Medical Center, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, China.
Qiong HuangDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Kelong AiXiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan, China.
Central South University · CNThe Fourth People's Hospital of Ningxia Hui Autonomous Region · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute kidney injury has always been considered a sword of Damocles over hospitalized patients and has received increasing attention due to its high morbidity, elevated mortality, and poor prognosis. Hence, AKI has a serious detrimental impact not only on the patients, but also on the whole society and the associated health insurance systems. Redox imbalance caused by bursts of reactive oxygen species at the renal tubules is the key cause of the structural and functional impairment of the kidney during AKI. Unfortunately, the failure of conventional antioxidant drugs complicates the clinical management of AKI, which is limited to mild supportive therapies. Nanotechnology-mediated antioxidant therapies represent a promising strategy for AKI management. In recent years, two-dimensional (2D) nanomaterials, a new subtype of nanomaterials with ultrathin layer structure, have shown significant advantages in AKI therapy owing to their ultrathin structure, large specific surface area, and unique kidney targeting. Herein, we review recent progress in the development of various 2D nanomaterials for AKI therapy, including DNA origami, germanene, and MXene; moreover, we discuss current opportunities and future challenges in the field, aiming to provide new insights and theoretical support for the development of novel 2D nanomaterials for AKI treatment.

Indexed as

acute kidney injuryantioxidant therapynanomaterialstargeted therapytwo-dimension

Identifiers

PMID36970615
PMCPMC10033996
OpenAlexW4323665974

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read6
measurements read11
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.